Endothel Pharma ApS: Financial statements 2019
CVR: 37988936
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Endothel Pharma ApS (CVR 37988936) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -23,142 and a net result of DKK -36,111 compared with DKK -59,310 the year before. Equity in the 2019 report amounted to DKK -51,535.
- Gross Profit
- DKK -23,142
- Profit/Loss
- DKK -36,111
- Equity
- DKK -51,535
- Total Assets
- DKK 331,330
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -23 t. | -36 t. | -52 t. | - |
| 2018 | - | -53 t. | -59 t. | -40 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Endothel Pharma ApS has published its annual report for 2018. Gross profit came to DKK -52,984, and the net result was DKK -59,310.
About Endothel Pharma ApS
Endothel Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rikke Stine Friis Fléron. The company is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -43,536 and a net result of DKK -87,006 compared with DKK -81,618 the year before. Equity in the 2025 report amounted to DKK -462,946.